Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
VistaGen Therapeutics ( (VTGN) ) just unveiled an update.
On May 12, 2026, Vistagen reported preliminary positive data from the ongoing open-label extension of its PALISADE-3 Phase 3 trial evaluating intranasal fasedienol for the acute treatment of social anxiety disorder. In 341 adults using as-needed dosing of fasedienol for up to 12 months, the drug was well-tolerated with low discontinuation due to adverse events, no serious adverse events attributed to the drug, and no new safety signals across laboratory tests, ECGs, and vital signs.
Exploratory results over the first four months showed clinically relevant and progressive improvements in social anxiety symptoms on both clinician-administered LSAS and patient-reported SPIN scales, including in patients who had not responded in the earlier randomized, single-dose portion that failed its primary endpoint in December 2025. These data, consistent with prior long-term safety and real-world studies, may support the potential for fasedienol as a real-world, as-needed treatment option and help sustain Vistagen’s broader PALISADE Phase 3 program, including the PALISADE-4 trial and a repeat-dose Phase 2 study.
The most recent analyst rating on (VTGN) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on VistaGen Therapeutics stock, see the VTGN Stock Forecast page.
Spark’s Take on VTGN Stock
According to Spark, TipRanks’ AI Analyst, VTGN is a Neutral.
The score is held down primarily by weak financial performance (large losses and significant ongoing cash burn on very small revenue) and longer-term bearish technical positioning (well below 100/200-day averages). Partially offsetting this are a low-leverage balance sheet and cautiously neutral clinical/program updates from the earnings call, while corporate events add both upside (refisolone U.S. Phase 2 clearance) and meaningful listing/governance overhangs (Nasdaq compliance issues).
To see Spark’s full report on VTGN stock, click here.
More about VistaGen Therapeutics
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on neuroscience, developing and commercializing a new class of intranasal product candidates known as pherines. The company’s lead program, fasedienol, targets nose-to-brain neurocircuitry for the acute treatment of social anxiety disorder, positioning Vistagen in the emerging market for rapid-acting, as-needed psychiatric therapies.
Average Trading Volume: 736,243
Technical Sentiment Signal: Sell
Current Market Cap: $24.19M
For an in-depth examination of VTGN stock, go to TipRanks’ Overview page.